Unión Europea - español - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merial s.a.s. - virus panleucopenia felina (pli-iv), virus rinotraqueitis infecciosa felina (herpesvirus),vivo atenuado,cepa f2, calicivirus felino, inactivado, cepa 431, calicivirus felino, inactivado, cepa g1, virus canaripox recombinante felv (vcp97) - suspensiÓn inyectable - excipientes: gentamicina - vacunas víricas vivas e inactivadas - gatos

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merial s.a.s. - virus rinotraqueitis infecciosa felina (herpesvirus),vivo atenuado,cepa f2, virus panleucopenia felina (pli-iv), calicivirus felino, inactivado, cepa 431, calicivirus felino, inactivado, cepa g1, virus canaripox recombinante felv (vcp97) - soluciÓn inyectable - excipientes: gentamicina - vacunas víricas vivas e inactivadas - gatos